Hyderabad: Biological E Limited (BE) on Tuesday announced a strategic partnership with Bavarian Nordic A/S (OMX: BAVA) to expand access to Bavarian Nordic's Chikungunya Vaccine in low-and middle-income countries (LMIC).
This partnership comprises a technology transfer of the current drug product manufacturing process for the Chikungunya Vaccine, with the option to transfer the drug substance process at a later stage. To that effect, the companies have reached an agreement to expand their capacity to provide future supplies to endemic low- and middle-income countries.
